
Novo Nordisk’s $475B Reversal: How the Wegovy Boom Turned Into a Competitive Reality Check
From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy era has officially come full circle. Shares of the Danish drugmaker plunged more than 16%, wiping out the remaining gains tied to the explosive growth








